Concordance of programmatic and laboratory-based multidrug-resistant tuberculosis treatment outcomes in Peru

E. R. Alexy, Laura Jean Podewils, C. D. Mitnick, M. C. Becerra, K. F. Laserson, C. Bonilla

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


BACKGROUND: Confirmation of cure for multidrugresistant tuberculosis (MDR-TB) patients requires laboratory tests for Mycobacterium tuberculosis growth on culture media. Outcome decisions dictate patient management, and inaccuracies place patients at an increased risk of morbidity and mortality, and may contribute to continued transmission of MDR-TB. OBJECTIVE: To examine concordance between programmatic and laboratory-based MDR-TB treatment outcomes. METHODS: The study population included 1658 MDRTB patients in Peru treated between 1996 and 2002 with both program and laboratory-based outcomes. Laboratory-based outcomes were assigned according to international standards requiring at least five consecutive negative cultures in the last 12 months of treatment to confirm cure. RESULTS: Compared to the global culture-defined standard classification, only 1.1% of treatment successes, but 54.3% of failures, were misclassified programmatically. Overall, 10.4% of patients identified by a clinician as having a successful treatment outcome still had cultures positive for MDR-TB. CONCLUSION: Most patients with successful treatment outcomes by strict culture definitions were also classified by clinicians as having successful outcomes. However, many culture-confirmed failures were missed. In light of delays and incomplete access to culture in MDR-TB programs, efforts should be made to improve the accuracy of programmatically determined treatment outcomes. © 2012 The Union.
Original languageAmerican English
Pages (from-to)364-369
Number of pages6
JournalInternational Journal of Tuberculosis and Lung Disease
StatePublished - 1 Mar 2012

Fingerprint Dive into the research topics of 'Concordance of programmatic and laboratory-based multidrug-resistant tuberculosis treatment outcomes in Peru'. Together they form a unique fingerprint.

Cite this